Catastrophism in Chronic Inflammatory Rheumatism

Study Overview
=================
Brief Summary
-----------------
Catastrophic is defined as a negative cognitive and emotional response based on inadequate pain expression. It has three components: rumination, amplification and vulnerability. The assessment of catastrophism is carried out using a validated questionnaire called the Pain Catatrophizing Scale (PCS). Recent studies highlight the significant impact of catastrophism in neuromuscular and mechanical rheumatic diseases such as gonarthrosis gonalgia and low back pain. In these diseases, it has been shown that catastrophism has a negative impact both on the experience of pain and on the response to different types of treatments (medical and surgical). Several studies have implemented multidisciplinary management and in particular cognitive-behavioural therapy with an improvement in the pain experience in patients who are catastrophic. In chronic inflammatory rheumatic diseases such as rheumatoid arthritis, spondyloarthritis and psoriatic arthritis, the prevalence and impact of catastrophism is still poorly understood.

Official Title
-----------------
Catastrophism in Chronic Inflammatory Rheumatism

Conditions
-----------------
Chronic Inflammatory Rheumatism

Intervention / Treatment
-----------------
* Other: completing self-questionnaires


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Major patients, hospital follow-up, with RA according to ACR 2010 criteria, or spondyloarthritis according to ASAS 2009 criteria or according to AMOR or psoriatic arthritis according to Caspar 2006 criteria. Patient who has given free and informed consent. Patient who has signed the consent form. Patient affiliated or benefiting from a health insurance plan. Adult patient (≥18 years old). Exclusion Criteria: Patient under the protection of justice, under guardianship or curatorship. Patient unable to express consent. Patient for whom it is impossible to provide informed information. Poor command and understanding of the French language making it impossible to complete self-questionnaires

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: rheumatoid arthritis<br>Filling in several self-questionnaires: on function (HAQ), pain EVA, quality of life (SF12, EQ5D), anxiety score (GAD-7), insomnia score (ISI), catastrophic score (PCS), coping score (coping ability, CSQ), compliance scores (CQR, Health Insurance Compliance Assessment Questionnaire) and fibromyalgia diagnostic score (FiRST), activity of rheumatic disease (RAID, RAPID-3) Patients will be seen at 3, 6 and 12 months | Other: completing self-questionnaires<br>* completing self-questionnaires on quality of life, anxiety, insomnia, activity of rheumatic disease and catastrophism<br>|
| Experimental: spondyloarthritis<br>Filling in several self-questionnaires: on function (HAQ), pain EVA, quality of life (SF12, EQ5D), anxiety score (GAD-7), insomnia score (ISI), catastrophic score (PCS), coping score (coping ability, CSQ), compliance scores (CQR, Health Insurance Compliance Assessment Questionnaire) and fibromyalgia diagnostic score (FiRST), activity of rheumatic disease (BASDAI, BASFI). Patients will be seen at 3, 6 and 12 months | Other: completing self-questionnaires<br>* completing self-questionnaires on quality of life, anxiety, insomnia, activity of rheumatic disease and catastrophism<br>|
| Experimental: Psoriatic arthritis<br>Filling in several self-questionnaires: on function (HAQ), pain EVA, quality of life (SF12, EQ5D), anxiety score (GAD-7), insomnia score (ISI), catastrophic score (PCS), coping score (coping ability, CSQ), compliance scores (CQR, Health Insurance Compliance Assessment Questionnaire) and fibromyalgia diagnostic score (FiRST), activity of rheumatic disease (BASDAI, BASFI). Patients will be seen at 3, 6 and 12 months | Other: completing self-questionnaires<br>* completing self-questionnaires on quality of life, anxiety, insomnia, activity of rheumatic disease and catastrophism<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| catastrophic assessment | Pain Catastrophism Scale (0= no catastrophism, 52 = maximum catastrophism) | Day 0 | 
| catastrophic assessment | Pain Catastrophism Scale (0= no catastrophism, 52 = maximum catastrophism) | at 3 months | 
| catastrophic assessment | Pain Catastrophism Scale (0= no catastrophism, 52 = maximum catastrophism) | at 6 months | 
| catastrophic assessment | Pain Catastrophism Scale (0= no catastrophism, 52 = maximum catastrophism) | at 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Catastrophism